Compare Nuwellis Inc (NUWE) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Sana Biotechnology Inc — how do they compare? Nuwellis Inc trades at $0.69 (market cap $2.20M), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: Sana Biotechnology Inc is far larger — about 380.3× Nuwellis Inc's market cap, and Nuwellis Inc is more actively traded (121,544 versus 4,507,444). Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and Sana Biotechnology Inc for 23 Days on average.
| NUWE | SANA | |
|---|---|---|
Market Cap | $2.20M | $836.71M |
Volume | 121,544 | 4,507,444 |
Sector | Health | Health |
52-Week High | $146.65 | $5.92 |
52-Week Low | $0.68 | $2.68 |
Typical Hold Time | 26 Days | 23 Days |
Enterprise Value | -$1.52M | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.689, down 0.25% with a bearish technical signal despite oversold RSI readings. The company shows promising revenue growth (14% YoY in Q2 2026) and strong gross margins (69.69%), but faces significant profitability challenges with a -125.63% net income margin and negative cash flow. Recent news highlights console adoption growth and strategic expansions in pediatric care.
While NUWE's valuation metrics appear attractive (P/E 0.03, P/S 0.01), the company's persistent losses and negative cash flow present substantial risk. Analyst sentiment is mixed with a 50/50 buy/hold split. The stock offers speculative potential if management can achieve profitability, but requires careful risk assessment given current financial challenges.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with no revenue, negative earnings, and substantial cash burn. The technical picture remains bearish with moving averages signaling continued downward pressure, though oscillators show neutral conditions. Recent earnings have been mixed with two misses and one beat against expectations, while analyst sentiment remains overwhelmingly positive with 82% buy ratings.
The outlook hinges on SANA's clinical pipeline success and future revenue generation capabilities. Investment opportunity exists in the company's promising biotechnology platform and strong analyst support, but risks include continued cash burn, lack of current revenue, and execution challenges in bringing therapies to market. The stock represents a high-risk, high-reward biotechnology investment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
